These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1384557)

  • 41. Tuberculosis recurrence in Africa: true relapse or re-infection?
    Daley CL
    Lancet; 1993 Sep; 342(8874):756-7. PubMed ID: 8103871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV seroincidence and correlates of seroconversion in a cohort of male factory workers in Harare, Zimbabwe.
    Mbizvo MT; Machekano R; McFarland W; Ray S; Bassett M; Latif A; Katzenstein D
    AIDS; 1996 Jul; 10(8):895-901. PubMed ID: 8828747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future.
    Lehloenya RJ; Dheda K
    Expert Rev Anti Infect Ther; 2012 Apr; 10(4):475-86. PubMed ID: 22512756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV testing and tuberculosis treatment outcome in a rural district in Malawi.
    Banerjee A; Moyo S; Salaniponi F; Harries A
    Trans R Soc Trop Med Hyg; 1997; 91(6):707-8. PubMed ID: 9509185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment outcomes of adult patients with recurrent tuberculosis in relation to HIV status in Zimbabwe: a retrospective record review.
    Takarinda KC; Harries AD; Srinath S; Mutasa-Apollo T; Sandy C; Mugurungi O
    BMC Public Health; 2012 Feb; 12():124. PubMed ID: 22329930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
    Schreiber J; Zissel G; Greinert U; Schlaak M; Müller-Quernheim J
    Eur J Med Res; 1999 Feb; 4(2):67-71. PubMed ID: 10066642
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tuberculin sensitivity and HIV-1 status of patients attending a sexually transmitted diseases clinic in Lusaka, Zambia: a cross-sectional study.
    Duncan LE; Elliott AM; Hayes RJ; Hira SK; Tembo G; Mumba GT; Ebrahim SH; Quigley M; Pobee JO; McAdam KP
    Trans R Soc Trop Med Hyg; 1995; 89(1):37-40. PubMed ID: 7747304
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pneumocystis carinii as a cause of pneumonia in HIV-infected patients in Lusaka, Zambia.
    Machiels G; Urban MI
    Trans R Soc Trop Med Hyg; 1992; 86(4):399-400. PubMed ID: 1440816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality.
    Nunn P; Brindle R; Carpenter L; Odhiambo J; Wasunna K; Newnham R; Githui W; Gathua S; Omwega M; McAdam K
    Am Rev Respir Dis; 1992 Oct; 146(4):849-54. PubMed ID: 1416409
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Infection and morbidity in patients with tuberculosis in Nairobi, Kenya.
    Brindle RJ; Nunn PP; Batchelor BI; Gathua SN; Kimari JN; Newnham RS; Waiyaki PG
    AIDS; 1993 Nov; 7(11):1469-74. PubMed ID: 8280413
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia.
    Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn PP
    J Trop Med Hyg; 1995 Feb; 98(1):9-21. PubMed ID: 7861484
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of thiacetazone.
    Wilkinson D; Moore D
    Lancet; 1995 Jan; 345(8941):63. PubMed ID: 7528313
    [No Abstract]   [Full Text] [Related]  

  • 53. Fine-needle extrathoracic lymph-node aspiration in HIV-associated sputum-negative tuberculosis.
    Pithie AD; Chicksen B
    Lancet; 1992 Dec 19-26; 340(8834-8835):1504-5. PubMed ID: 1361599
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thiacetazone skin reaction in Papua New Guinea.
    Naraqi S; Temu P
    Med J Aust; 1980 May; 1(10):480-1. PubMed ID: 6157976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone-free antituberculosis treatment in Yaounde, Cameroon.
    Kuaban C; Bercion R; Koula-Shiro S
    Cent Afr J Med; 1998 Feb; 44(2):34-7. PubMed ID: 9675969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatic complications of antituberculous therapy.
    Rossouw JE; Saunders SJ
    Q J Med; 1975 Jan; 44(173):1-16. PubMed ID: 50605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug regimen for tuberculosis without thiacetazone and streptomycin.
    Biddulph J
    Lancet; 1991 May; 337(8750):1174. PubMed ID: 1709250
    [No Abstract]   [Full Text] [Related]  

  • 58. Rebuttal: time to call a halt to emotions in the assessment of thioacetazone.
    Rieder HL; Enarson DA
    Tuber Lung Dis; 1996 Apr; 77(2):109-11. PubMed ID: 8762843
    [No Abstract]   [Full Text] [Related]  

  • 59. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa--fifth investigation. A co-operative study in East African hospitals, clinics and laboratories with the collaboration of the East African and British Medical Research Councils.
    Tubercle; 1970 Jun; 51(2):123-51. PubMed ID: 4099678
    [No Abstract]   [Full Text] [Related]  

  • 60. The impact of HIV on infectiousness of pulmonary tuberculosis: a community study in Zambia.
    Elliott AM; Hayes RJ; Halwiindi B; Luo N; Tembo G; Pobee JO; Nunn PP; McAdam KP
    AIDS; 1993 Jul; 7(7):981-7. PubMed ID: 8357557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.